Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Scientific Research Publishing

CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report ()

Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .

Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus

Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...
Border Counties Advertizer

Family donate £400 to RJAH Montgomery Unit in Shropshire

The donation was made to the Montgomery Unit at The Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH) by Jean Kilvert, ...

What's Going On With Iovance Biotherapeutics Stock On Friday?

Iovance stock jumps despite no news as investors watch short interest and promising early data from its cancer therapy trial.
Healio

Negative pressure wound therapy did not reduce infection rate for soft tissue sarcoma

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...